Trial · NCT05477563
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Fetal Hemoglobin (HbF) Concentration Over Time | Up to 12 Months After CTX001 Infusion | |
| Primary | Total Hemoglobin (Hb) Concentration Over Time | Up to 12 Months After CTX001 Infusion | |
| Secondary | TDT and SCD: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | From Signing of Informed Consent up to 12 Months After CTX001 Infusion | |
| Secondary | TDT and SCD: Proportion of Participants With Engraftment (First day of 3 Consecutive Measurements of Absolute Neutrophil Count (ANC) >=500 per Microliter [mcgL] on 3 Different Days) | Within 42 Days After CTX001 Infusion | |
| Secondary | TDT and SCD: Time to Engraftment | Up to 12 Months After CTX001 Infusion | |
| Secondary | TDT and SCD: Incidence of Transplant-Related Mortality (TRM) Within 100 Days After CTX001 Infusion | Within 100 Days After CTX001 Infusion | |
| Secondary | TDT and SCD: Incidence of TRM Within 12 Months After CTX001 Infusion | Within 12 Months After CTX001 Infusion | |
| Secondary | TDT and SCD: Incidence of All-cause Mortality | From Signing of Informed Consent up to 12 Months After CTX001 Infusion | |
| Secondary | TDT and SCD: Relative Reduction in Annualized Volume of RBC Transfusions | From Day 60 up to 12 Months After CTX001 Infusion | |
| Secondary | TDT and SCD: Proportion of Alleles With Intended Genetic Modification Present in Peripheral Blood Over Time | Up to 12 Months After CTX001 Infusion | |
| Secondary | TDT and SCD: Proportion of Alleles With Intended Genetic Modification Present in CD34+ Cells of the Bone Marrow Over Time | Up to 12 Months After CTX001 Infusion | |
| Secondary | TDT: Duration Transfusion Free in Participants | Up to 12 Months After CTX001 Infusion | |
| Secondary | SCD: Relative Reduction in Annualized Rate of Severe Vaso-Occlusive Crises (VOCs) | From Baseline up to 12 Months After CTX001 Infusion | |
| Secondary | SCD: Relative Reduction in Annualized Rate of Inpatient Hospitalizations for Severe VOCs | From Baseline up to 12 Months After CTX001 Infusion | |
| Secondary | SCD: Relative Reduction in Annualized Duration of Hospitalization for Severe VOCs | From Baseline up to 12 Months After CTX001 Infusion | |
| Secondary | SCD: Relative Reduction in Haptoglobin | From Baseline up to 12 Months After CTX001 Infusion | |
| Secondary | SCD: Relative Reduction in Lactate dehydrogenase | From Baseline up to 12 Months After CTX001 Infusion | |
| Secondary | SCD: Relative Reduction in Total Bilirubin | From Baseline up to 12 Months After CTX001 Infusion | |
| Secondary | SCD: Relative Reduction in Indirect Bilirubin | From Baseline up to 12 Months After CTX001 Infusion |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05477563/registered